Groupama Asset Managment Acquires Shares of 1,204,952 Exact Sciences Co. (NASDAQ:EXAS)

Groupama Asset Managment purchased a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,204,952 shares of the medical research company's stock, valued at approximately $821,000. Groupama Asset Managment owned approximately 0.65% of Exact Sciences as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. WCM Investment Management LLC boosted its stake in Exact Sciences by 1,153.2% during the 3rd quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company's stock valued at $12,388,000 after acquiring an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. grew its stake in Exact Sciences by 67.5% in the third quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company's stock worth $1,994,000 after purchasing an additional 11,800 shares in the last quarter. Profund Advisors LLC increased its holdings in Exact Sciences by 239.8% in the second quarter. Profund Advisors LLC now owns 78,589 shares of the medical research company's stock valued at $3,320,000 after buying an additional 55,459 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Exact Sciences by 59.5% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company's stock valued at $22,868,000 after buying an additional 125,192 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Exact Sciences by 3.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company's stock valued at $88,017,000 after buying an additional 45,015 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

Analyst Ratings Changes

Several research firms have recently issued reports on EXAS. Jefferies Financial Group increased their price objective on shares of Exact Sciences from $84.00 to $85.00 and gave the company a "buy" rating in a report on Wednesday, November 6th. Wells Fargo & Company began coverage on Exact Sciences in a research note on Tuesday, August 27th. They set an "overweight" rating and a $75.00 price target for the company. Robert W. Baird dropped their price objective on Exact Sciences from $70.00 to $67.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. TD Cowen raised their target price on Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, Stifel Nicolaus dropped their price target on shares of Exact Sciences from $82.00 to $67.00 and set a "buy" rating on the stock in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, Exact Sciences has an average rating of "Moderate Buy" and an average target price of $75.29.

Insider Buying and Selling

In other news, CEO Kevin T. Conroy bought 19,500 shares of the firm's stock in a transaction on Wednesday, November 13th. The stock was acquired at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the transaction, the chief executive officer now directly owns 1,074,191 shares of the company's stock, valued at $55,159,707.85. This represents a 1.85 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Brian Baranick sold 929 shares of the company's stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $70.00, for a total transaction of $65,030.00. Following the sale, the executive vice president now owns 12,758 shares in the company, valued at $893,060. The trade was a 6.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.36% of the stock is owned by company insiders.

Exact Sciences Price Performance

NASDAQ:EXAS traded down $0.22 during mid-day trading on Tuesday, reaching $61.58. The stock had a trading volume of 1,494,311 shares, compared to its average volume of 2,632,750. The stock has a 50-day simple moving average of $63.03 and a two-hundred day simple moving average of $56.55. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The stock has a market capitalization of $11.40 billion, a PE ratio of -52.63 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $708.66 million during the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative net margin of 7.95% and a negative return on equity of 6.17%. The firm's quarterly revenue was up 12.8% compared to the same quarter last year. On average, equities analysts anticipate that Exact Sciences Co. will post -1.13 earnings per share for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.